Skip to Main Content

Paper Details

Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.
Urol Oncol
4
2023
324 genes, 95 loci, GA, MTAP, MTAP loss mutations, MTAP-, MTAP- UCB, MTAP- tumors, Tumor, UCB, arginine, cyclin-dependent kinase inhibitor, cyclin-dependent kinase inhibitor 2A/B, fibroblast growth factor receptor 3, methylthioadenosine, methylthioadenosine phosphorylase, patients, phosphatase and tensin homolog GA, programmed death-ligand 1, protein arginine methyltransferase 5, sequenced DNA, tumor, tumors, urothelial bladder cancer, urothelial carcinoma of the bladder
Author NameAffiliation
Shakti H RamkissoonFoundation Medicine
Jeffrey S RossUpstate Medical University Department of Urology, NY Upstate Medical University Department of Medicine, NY Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Italy Foundation Medicine
  • 1 - 2

Datasets

Release 1.2